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Methods: VERIFY Pre-Op TIMI 45 was a prospective study of 42 patients with
indications for coronary angiography subsequently referred for CABG. All patients were
therapeutic on clopidogrel. Platelet function was assessed with VerifyNow™ P2Y12
Reaction Units (PRU). Chest tube output within 24-hours of CABG was stratified by PRU
 208,  230, and  275. Results reported as meanSD.
Results: Median time from last clopidogrel dose to CABG was 4 days (range 1 to 9
days). Patients who held clopidogrel 4 days had lower PRU than those who held for
4 days (19084 vs. 27121 PRU; p0.015). Thresholds of PRU  208 or  275
correlated with less bleeding but did not reach significance (p0.20 and p0.39). Patients
with PRU  230 had significantly less chest tube output than those with PRU  230
(622220 vs. 1028676; p0.026) (Figure).
Conclusions: The VerifyNow™ P2Y12 platelet function assay can be used to predict
perioperative bleeding in patients exposed to clopidogrel undergoing CABG. A threshold
of 230 PRU is associated with less bleeding, and may assist clinicians in optimizing the
timing of surgery.
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Background: High on-treatment platelet reactivity (HPR) has been identified as an
independent risk factor for ischemic events in acute coronary syndrome (ACS) patients
(pts). In TRIPLET, ACS pts undergoing percutaneous coronary intervention (PCI) were
given a prasugrel (pras) loading dose (LD) with or without a prior clopidogrel (clop) LD.
An analysis of HPR was included.
Methods: TRIPLET was a randomized, double-blind study in ACS-PCI pts on aspirin
using VerifyNow P2Y12 assay to evaluate Pras with or without prior Clop in 3 arms: (1)
placebo (PBO) followed by Pras 60-mg LD (2) Clop 600-mg LD followed by Pras 30-mg
LD (3) Clop 600-mg LD followed by Pras 60-mg LD. Pts undergoing PCI received Pras
10-mg once daily (qd) for 2-4 days. HPR (P2Y12 Reaction Units [PRU] 240) were
evaluated in the pharmacodynamic population within 24 hrs following the PBO/Clop LD,
immediately prior to Pras LD and at 2, 6, 24, 72 hrs following Pras LDs.
Results: HPR following Clop was 58.5% in the combined Clop LD arms. No substantial
difference was noted when stratified by time between the Clop and Pras LDs ( 6hrs vs
6 hrs). At 6 hrs in the combined Pras LD arms, HPR was 7.1%, with 0% HPR by 72
hrs. Because a high number of HPR occurred in a single site, a statistical outlier analysis
was performed. When outliers were excluded, HPR occurred in 1.9% at 6 hours and in 0%
by 24 hrs.
Conclusions: In TRIPLET, pts with ACS intended for PCI showed a high prevalence of
HPR after Clop 600-mg LD, even when measured after 6 hrs. When Pras LD was added,
HPR decreased substantially by 6 hrs and was absent by 72 hrs.
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Background: Clopidogrel loading dose of 600mg is used in patients undergoing PCI and
those treated for acute coronary syndromes. 600mg of clopidogrel can significantly inhibit
platelet inhibition within 2 hours but also improve endothelial dysfunction in stable CAD
patients via a mechanism independent of platelet function. We sought to study the effect
of both acute clopidogrel 600mg loading and chronic 75mg therapy on markers of NO
metabolism, vasodilatory effect and antioxidant status in these patients.
Methods: 58 CAD patients were recruited. In the clopidogrel naive group (36 subjects)
blood was taken before and 2h after 600mg dose of clopidogrel and 75mg aspirin
(ASA)who were attending for PCI for stable angina. We studied another cohort on chronic
ASA and clopidogrel 75mg (22 subjects) after 2 months of therapy. All plasma samples
were measured for NO metabolites (nitrite, nitrate and S-nitrosothiols), cGMP (a marker
of vasodilatory effect) and antioxidant capacity of the plasma (ORAC index). Pearson
correlation statistics were performed on all acute pre and post clopidogrel loading and
chronic therapy to explore the relationships seen in NO metabolites.
Results: 2 hours after clopidogrel 600mg dose, plasma nitrite was increased from
157.182.4 to 194.287.64 nM (p0.012), cGMP from 214.2124.4 to 231.5107.8
pmol/ml(p0.05) and ORAC index from 60.6611.45 to 64.1510.61%(p0.037).
Acute loading - the rise in cGMP was inversely related to the total antioxidant capacity
of the plasma (ORAC index)p0.0001 also the rise in nitrite with the increase in cGMP
p0.0043. There was a weaker correlation in the rise in nitrate as a consequence of
600mg with the rise in ORAC p0.0782. After chronic clopidogrel, nitrite was increased
from 157.182.4 to 254.3139.4nM(p0.0028), as well as cGMP from 214.2124.4 to
276.972.15pmol/ml(p0.05). In both acute and chronic groups RSNO (nitrosothiol)
was unchanged.
Conclusions: Patients receiving clopidogrel exhibit a time-proportional increase in NO
bioavailability and effective vasodilation. Clopidogrel has beneficial effects on redox
status 2 hours after 600mg. These results suggest non platelet - pleiotropic effects of
clopidogrel in CAD patients.
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Background: The clinical use of genetic testing in ACS is limited by accessibility and
turn-around-time. Nanosphere Verigene® System is a novel point-of-care (POC) genetic
test analyzing 11 CYP2C19 variants within 3 hours. We evaluated the accuracy of the
method to identify extensive (EM) and reduced clopidogrel (clop) metabolizers (RM) in
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stable coronary artery disease (CAD) patients by comparing the results to an established,
validated laboratory-based genotyping method.
Methods: 74 stable CAD patients on clop 75 mg daily were tested by clinical nurses with
no genetic laboratory experience and 1 hour of basic training on the device. The patients
were defined as EM (*1/*1, *1/*17, *17/*17), RM (*1/*2A, *1/*8, *2A/*2A, *2A/*3).
Genetic testing was conducted on 1 mL of whole blood using the Verigene® System and
compared to an Affymetrix® DMET	 assay. Pharmacokinetic (PK) exposure to clop’s
active metabolite (AM) was measured and platelet reactivity (PD) was assessed with the
VerifyNow™ P2Y12 system (PRU) and VASP (PRI) assays.
Results: There was an overall 99.9% concordance of marker-level data between the
Verigene® and the reference (DMET	) in measuring the CYP2C19 markers of interest.
There was a 100% agreement between Verigene® and the reference test in classifying the
patients into established EM and RM groups. The POC assay identified 59 EM, 15 RM.
The EM group had significantly lower PRU (LS means 158 vs. 212; p0.003), and PRI
(LS means 48 vs. 63, p0.01) than RM group treated with clopidogrel 75 mg. The EM
group also had significantly higher AM exposure by AUC(0-last) than the RM group (LS
means 12.6 vs. 7.7; p0.0009).
Conclusions: This is the first report of a POC genetic testing platform performing a
comprehensive CYP2C19 polymorphism characterization in CAD patients and validating
the genotypes against the PK and PD phenotype. There was a high concordance between
the two platforms in measuring the star allele marker data. The POC genetic test identified
EM and RM phenotypes based on 11 gene variants with high accuracy and predicted a
reduced platelet inhibition in response to clop. A rapid, reliable POC CYP2C19 genetic
test could make clop pharmacogenetic testing feasible for all patients.
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Background: There is no consensus concerning the usefulness of routine assessment of
in vitro platelet reactivity for recognition of clopidogrel nonresponders, or the method or
methods that allow reliable assessment of residual platelet reactivity, and for each method
the cutoff of platelet aggregation inhibition that should be used in clinical practice.
Methods: The study includes 1,789 acute coronary syndrome (ACS) patients receiving
an invasive treatment and for whom platelet reactivity after a 600 mg clopidogrel loading
was prospectively assessed by light transmittance aggregometry (LTA). The primary end
point of the study was a composite of cardiac death, myocardial infarction, any urgent
coronary revascularization, and stroke (MACE) at 2-year follow-up; the secondary end
point was cardiac mortality. The sensitivity and specificity of platelet reactivity to predict
both end points were calculated in a ROC curve analysis. The optimal cutoff value was
defined by the highest Youden index value and compared with the predefined cutoff of
70% used in the main study and corresponding to the 90th percentile value derived from
an healthy volunteer sample.
Results: By ROC analysis 63% resulted the optimal cutoff value to predict both MACE
and cardiac death at 2 years of follow-up. A significant sensitivity improvement for the
ROC-based cutoff value was revealed (32%; p0.001). The incidence of clopidogrel
nonresponders changed from 14% with the cutoff of 70% to 24% with the ROC-based
cutoff. However, the increased sensitivity was reached at the price of a lower specificity
and accuracy. The latter with the cutoff of 70% was 81% for MACE and 84% for cardiac
death, while with the cutoff of 63% the predictive accuracy was 73% and 75%,
respectively. The AUCs were nearly identical with the 2 cutoffs both for MACE (0.71;
95% CI 0.69-0.73) and cardiac death (0.79; 95% CI 0.77-0.81).
Conclusions: The cutoff of 70% as compared to the ROC-based of 63% allows the
identification of a subset of patients at very high risk of cardiac death in only 14% of the
studied population, making the ADP LAT test more acceptable in clinical practice for the
identification of subjects at risk.
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Background: Glycoprotein IIb/IIIa inhibitors (GPI) are widely used during percutaneous
interventions, particularly in the setting of high clot burden, slow flow, or no reflow. While
the safety of a 300 mg clopidogrel loading dose in conjunction with GPI therapy has been
established, the safety of a 600 mg clopidogrel load has not been defined.
Methods: We searched PubMed, Cochrane, and ClinicalTrials.gov for studies that
involved PCI in patients treated with a GPI plus either 300 mg or 600 mg of clopidogrel.
We excluded studies that involved oral or intracoronary GPI therapy and/or thrombolysis.
Results: Our study included 15 trials and 12,114 patients. Major bleeding incidence
ranged from 0% to 10.36% with 300 mg of clopidogrel versus 1.11% to 7.52% with 600
mg of clopidogrel. Minor bleeding incidence ranged from 0% to 25.69% with 300 mg of
clopidogrel and from 0% to 6.13% with 600 mg of clopidogrel. After excluding trials that
did not define bleeding based on TIMI criteria, the pooled incidence of major bleeding
was 1.08 (95% CI, 0.74 to 1.42)% for the 300 mg clopidogrel group and 1.46 (95% CI,
1.02-1.90)% for the 600 mg clopidogrel group (p0.91) (Figure 1A). The pooled
incidence of TIMI minor bleeding was 2.15 (95% CI, 0.44 to 3.86)% for the 300 mg group
and 3.66 (95% CI, 2.54 to 4.79)% for the 600 mg group (p0.46) (Figure 1B).
Conclusions: Among patients undergoing PCI and receiving a GPI, the incidence of
bleeding is low and similar after a 300 mg or 600 mg clopidogrel loading dose.
TCT-728
Clinical presentations, antiplatelet strategies and prognosis of patients with
stent thrombosis: an observational study of 140 patients
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Background: Until now there has been scarce evidence regarding an optimal antiplatelet
strategy and clinical outcomes for patients who had suffered from stent thrombosis (ST).
Methods: 140 patients who suffered from stent thrombosis were prospectively registered.
Patients received dual (aspirin and 150mg clopidogrel, N66) or triple (additional
cilostazol, N74) antiplatelet therapy at the physician’s discretion. Thereafter platelet
reactivity and one year clinical outcomes were analyzed. The primary outcome included
the composite of cardiac death, non-fatal myocardial infarction (MI) or stroke at one year.
Results: MACE developed in 41 (29.3%) patients, consisting of 31 (22.1%) cardiac
death, 9 (6.4%) non-fatal MI and 1 (1.4%) stroke. Recurrent definite and probable ST
according to ARC definition was observed in 8 (5.7%) and 14 (10.0%) patients,
respectively. Triple therapy was associated with significantly lower platelet reactivities
(50.217.8, % vs. 59.617.2, %, P0.002) compared to high dose dual antiplatelet
therapy. However, the incidence of primary events (24.3% vs. 34.8%, P0.172) did not
differ between triple and dual antiplatelet therapies. High on-treatment platelet reactivity
(HR: 8.35, 95% CI: 2.23430.867, P0.002) and diabetes (HR: 3.732, 95% CI:
1.35310.298, P0.011) were independent predictors of primary events.
Conclusions: Patients who suffered from stent thrombosis have a poor prognosis even
after revascularization with intensive antiplatelet therapy. Triple antiplatelet therapy was
more effective in reducing on-treatment platelet reactivity, compared to high dose dual
antiplatelet therapy.
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Background: The timing and incidence of adverse events by different durations of
clopidogrel therapy after SVG PCI remain unknown. The primary objective of this study
was to investigate the risk associated with cessation of long-term clopidogrel therapy after
SVG PCI.
Methods: This is a cohort study of patients undergoing SVG PCI from 2000-2009
followed for death or MI after stopping clopidogrel. A piecewise exponential survival
model was used to generate adjusted incidence rate ratios comparing the 0-90 day and
91-365 day intervals after clopidogrel cessation. A multivariate Cox regression model was
constructed to obtain risk-adjusted instantaneous incidence rates using kernel hazard
functions.
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